CG Oncology’s Promising Phase 3 Data and Market Potential Justify Buy Rating

Sean Laaman, an analyst from Morgan Stanley, reiterated the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associated price target remains the same with $55.00.

Sean Laaman has given his Buy rating due to a combination of factors that highlight CG Oncology’s promising clinical data and potential market impact. The company’s recent Phase 3 BOND-003 Cohort C data update demonstrated a strong complete response rate for cretostimogene, with significant durability observed at 12 and 24 months. This data suggests a compelling efficacy profile, which is further supported by the absence of severe treatment-related adverse events, indicating a favorable safety profile.
Additionally, the upcoming presentation of the final monotherapy results at the American Urological Association meeting is anticipated to reinforce these findings, potentially showcasing even more robust data. Management’s confidence in the mature 24-month complete response rate, along with key opinion leaders emphasizing the importance of treatment durability and safety, further underscores the stock’s potential. These elements collectively contribute to the positive outlook and the Buy rating for CG Oncology’s stock.

In another report released on April 8, LifeSci Capital also maintained a Buy rating on the stock with a $82.00 price target.